TCR² Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast
- Earnings to be released after market close on
Monday, May 13, 2019
TCR2 will webcast its first quarter 2019 earnings conference call on Monday, May 13, 2019, beginning at 5:00 PM ET. The live audio webcast can be accessed by clicking on the Events link in the "Investors" section of www.tcr2.com. A replay of the call will also be archived on the website and will be available until the company’s next quarterly earnings call.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T™ cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarincoma. For more information about TCR2, please visit www.tcr2.com.
Chief Financial Officer
Source: TCR2 Therapeutics